| First Author | Randriamboavonjy V | Year | 2012 |
| Journal | Blood | Volume | 120 |
| Issue | 2 | Pages | 415-23 |
| PubMed ID | 22665935 | Mgi Jnum | J:189100 |
| Mgi Id | MGI:5444345 | Doi | 10.1182/blood-2011-12-399980 |
| Citation | Randriamboavonjy V, et al. (2012) Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. Blood 120(2):415-23 |
| abstractText | Platelets from patients with diabetes are hyperreactive and demonstrate increased adhesiveness, aggregation, degranulation, and thrombus formation, processes that contribute to the accelerated development of vascular disease. Part of the problem seems to be dysregulated platelet Ca(2+) signaling and the activation of calpains, which are Ca(2+)-activated proteases that result in the limited proteolysis of substrate proteins and subsequent alterations in signaling. In the present study, we report that the activation of mu- and m-calpain in patients with type 2 diabetes has profound effects on the platelet proteome and have identified septin-5 and the integrin-linked kinase (ILK) as novel calpain substrates. The calpain-dependent cleavage of septin-5 disturbed its association with syntaxin-4 and promoted the secretion of alpha-granule contents, including TGF-beta and CCL5. Calpain was also released by platelets and cleaved CCL5 to generate a variant with enhanced activity. Calpain activation also disrupted the ILK-PINCH-Parvin complex and altered platelet adhesion and spreading. In diabetic mice, calpain inhibition reversed the effects of diabetes on platelet protein cleavage, decreased circulating CCL5 levels, reduced platelet-leukocyte aggregate formation, and improved platelet function. The results of the present study indicate that diabetes-induced platelet dysfunction is mediated largely by calpain activation and suggest that calpain inhibition may be an effective way of preserving platelet function and eventually decelerating atherothrombosis development. |
